Research presented in February at the Symposium on Clinical Interventional Oncology (CIO), held in conjunction with International Symposium on Endovascular Therapy (ISET), in Hollywood, USA, provides a clear shot in the arm for chemoembolization that uses doxorubicin and ethiodised oil over the triple-drug version.
Nipro North America, a division of Nipro Medical Corporation, has launched the Cronus HP high-pressure, 0.035” over-the-wire percutaneous transluminal angioplasty balloon catheter.
The first clinical procedure with the Magellan robotic catheter eKit (MRC eKit, Hansen Medical) has been successfully performed. The device was used as part of a robotic transarterial chemoembolization procedure, which was completed by Ripal Gandhi at Miami Cardiac & Vascular Institute, Miami, USA.
The final results from a phase 2 randomised trial, published online in the Journal of Clinical Oncology on 1 February, find no benefit from using doxorubicin-eluting beads (LC Bead, BTG) over embolic microspheres that do not elute a drug (Bead Block, BTG).
The first liver cancer patient has been treated with LC Bead Lumi radiopaque embolic bead (BTG) in conjunction with Philips Live Image Guidance, targeting a hypervascular tumour with the goal of blocking blood flow to achieve tumour necrosis.
Preliminary results of a randomised controlled trial comparing the use of the Zilver PTX drug-eluting stent (Cook Medical) and bypass grafts in long femoropopliteal lesions show a trend in favour of the endovascular device at 12 months with lower rates of restenosis and target lesion revascularisation. Initial results of the ZILVERPASS study were presented at the Leipzig Interventional Course (LINC; 26–29 January 2016, Leipzig, Germany).
With the Magellan robotic catheter eKit, physicians will now have robotic control of third party microcatheters through the existing Magellan Robotic Catheter 6F architecture. This added ability has the potential to help reduce procedure times and radiation exposure.
The Society for Vascular Surgery (SVS), the American Podiatric Medical Association (APMA) and the Society for Vascular Medicine (SVM) collaboratively have published their first-ever set of clinical practice guidelines for treating the diabetic foot, based on a meta-analysis of the available literature.
Primary endpoint data from a prospective, multicentre clinical study evaluating the everlinQ endoAVF system have been announced by TVA Medical. The system is designed to an arteriovenous (AV) fistula for haemodialysis access in people with end-state kidney disease (ESKD) using an endovascular approach in vessels not traditionally used during surgery.
Positive six-month results from Intact Vascular’s TOBA-BTK (Tack Optimised Balloon Angioplasty—Below-the-Knee) clinical study have been reported at LINC 2016. The data were presented by principal investigator, Marianne Brodman, head of the Clinical Division of Angiology, at Medical University of Graz in Austria.
CE mark approval has been granted to Biotronik for smaller diameters of the Passeo-18 Lux drug-coated balloon (DCB). The new sizes—2mm and 2.5mm—are designed to facilitate DCB treatment of below-the-knee arteries.
Contego Medical presented positive post-market registry data for the Paladin carotid post-dilation balloon with Integrated Embolic Protection Technology at the Leipzig Interventional Course (LINC) 2016, in Leipzig, Germany.
Vascular Solutions has announced the US launch of its enhanced line of VSI Radial introducer sheaths for use in the introduction of guidewires and catheters into veins and arteries. The VSI Radial introducer sheaths are specifically designed for patients undergoing transradial catheterisation procedures, one of the fastest-growing practices in the field of interventional cardiology in the USA.
A single-centre, retrospective study published online in December 2015 in the Journal of Vascular and Interventional Radiology (JVIR), set out to review the safety and feasibility of using transradial access for non-coronary interventions.
A new analysis of the MORE data on 606 mCRC patients treated with SIR-Spheres Y-90 resin microspheres at 11 US medical centres, published late last year in Clinical Colorectal Cancer, confirms that patient age is not a barrier to appropriate treatment with the product, Sirtex has reported.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos